Vaniprevir

Vaniprevir
Identifiers
	IUPAC name (1R,21S,24S)-21-tert-butyl-N-[(1R,2R)-1-(cyclopropylsulfonylcarbamoyl)-2-ethylcyclopropyl]-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]heptacosa-6(11),7,9-triene-24-carboxamide;
CAS Number	923590-37-8;
PubChem CID	24765256;
DrugBank	DB11929;
ChemSpider	24651717;
UNII	CV3X74AO1H;
ChEBI	CHEBI:136047;
ChEMBL	ChEMBL4525964;
CompTox Dashboard (EPA)	DTXSID201029738 ;
ECHA InfoCard	100.207.830
Chemical and physical data
Formula	C38H55N5O9S
Molar mass	757.94 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@@H]1C[C@@]1(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)OCC(CCCCC5=C6CN(CC6=CC=C5)C(=O)O4)(C)C)C(C)(C)C;
	InChI InChI=InChI=1S/C38H55N5O9S/c1-7-25-18-38(25,33(46)41-53(49,50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2,3)4)39-34(47)51-22-37(5,6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10,12-13,25-27,29-30H,7-9,11,14-22H2,1-6H3,(H,39,47)(H,40,44)(H,41,46)/t25-,26-,29+,30-,38-/m1/s1; Key:KUQWGLQLLVFLSM-ONAXAZCASA-N;

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing.^[1] In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.^[2]^[3]

References

^ McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, et al. (March 2010). "Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor". J. Med. Chem. 53 (6): 2443–63. doi:10.1021/jm9015526. PMID 20163176.
^ "First recommendation for HCV drug vaniprevir, in Japan". datamonitorhealthcare.com. September 25, 2014.
^ "New Drugs Approved" (PDF). Pharmaceuticals and Medical Devices Agency. Archived from the original (PDF) on 2015-05-13. Retrieved 2015-08-22.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.